|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 33577 |
FusionGeneSummary for SGMS1_PSMB2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: SGMS1_PSMB2 | Fusion gene ID: 33577 | Hgene | Tgene | Gene symbol | SGMS1 | PSMB2 | Gene ID | 259230 | 5690 |
| Gene name | sphingomyelin synthase 1 | proteasome subunit beta 2 | |
| Synonyms | MOB|MOB1|SMS1|TMEM23|hmob33 | HC7-I | |
| Cytomap | 10q11.23 | 1p34.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | phosphatidylcholine:ceramide cholinephosphotransferase 1medulla oblongata-derived proteinprotein Mobtransmembrane protein 23 | proteasome subunit beta type-2macropain subunit C7-Imulticatalytic endopeptidase complex subunit C7-1multicatalytic endopeptidase complex subunit C7-Iproteasome (prosome, macropain) subunit, beta type, 2proteasome beta 2 subunitproteasome component | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | Q86VZ5 | P49721 | |
| Ensembl transtripts involved in fusion gene | ENST00000361781, ENST00000429490, ENST00000492601, ENST00000361543, | ENST00000373237, | |
| Fusion gene scores | * DoF score | 7 X 4 X 6=168 | 5 X 4 X 3=60 |
| # samples | 7 | 6 | |
| ** MAII score | log2(7/168*10)=-1.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(6/60*10)=0 | |
| Context | PubMed: SGMS1 [Title/Abstract] AND PSMB2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | SGMS1 | GO:0006686 | sphingomyelin biosynthetic process | 14685263|14976195 |
| Hgene | SGMS1 | GO:0046513 | ceramide biosynthetic process | 25605874 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | BRCA | TCGA-EW-A1OV-01A | SGMS1 | chr10 | 52193236 | - | PSMB2 | chr1 | 36102033 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5UTR-3CDS | ENST00000361781 | ENST00000373237 | SGMS1 | chr10 | 52193236 | - | PSMB2 | chr1 | 36102033 | - |
| intron-3CDS | ENST00000429490 | ENST00000373237 | SGMS1 | chr10 | 52193236 | - | PSMB2 | chr1 | 36102033 | - |
| intron-3CDS | ENST00000492601 | ENST00000373237 | SGMS1 | chr10 | 52193236 | - | PSMB2 | chr1 | 36102033 | - |
| intron-3CDS | ENST00000361543 | ENST00000373237 | SGMS1 | chr10 | 52193236 | - | PSMB2 | chr1 | 36102033 | - |
Top |
FusionProtFeatures for SGMS1_PSMB2 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| SGMS1 | PSMB2 |
| Sphingomyelin synthases synthesize the sphingolipid,sphingomyelin, through transfer of the phosphatidyl head group,phosphatidylcholine, on to the primary hydroxyl of ceramide. Thereaction is bidirectional depending on the respective levels ofthe sphingolipid and ceramide. Golgi apparatus SMS1 directly andspecifically recognizes the choline head group on the substrate,requiring two fatty chains on the choline-P donor molecule inorder to be recognized efficiently as a substrate. Major form inmacrophages. Required for cell growth in certain cell types suchas HeLa cells. Suppresses BAX-mediated apoptosis and also preventscell death in response to stimuli such as hydrogen peroxide,osmotic stress, elevated temperature and exogenously suppliedsphingolipids. May protect against cell death by reversing thestress-inducible increase in levels of proapoptotic ceramide.{ECO:0000269|PubMed:14685263, ECO:0000269|PubMed:17449912}. | Component of the 20S core proteasome complex involved inthe proteolytic degradation of most intracellular proteins. Thiscomplex plays numerous essential roles within the cell byassociating with different regulatory particles. Associated withtwo 19S regulatory particles, forms the 26S proteasome and thusparticipates in the ATP-dependent degradation of ubiquitinatedproteins. The 26S proteasome plays a key role in the maintenanceof protein homeostasis by removing misfolded or damaged proteinsthat could impair cellular functions, and by removing proteinswhose functions are no longer required. Associated with the PA200or PA28, the 20S proteasome mediates ubiquitin-independent proteindegradation. This type of proteolysis is required in severalpathways including spermatogenesis (20S-PA200 complex) orgeneration of a subset of MHC class I-presented antigenic peptides(20S-PA28 complex). {ECO:0000269|PubMed:15244466,ECO:0000269|PubMed:27176742, ECO:0000269|PubMed:8610016}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for SGMS1_PSMB2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for SGMS1_PSMB2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| SGMS1 | ATXN1, STK4, PTAR1, TRIM25 | PSMB2 | SLX1B, UBC, PSMA2, RAD23A, PSMA1, PSMB3, FKBP8, UCHL5, POMP, PSMB1, PSMB5, PSMB7, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB4, PSMB6, PSMB8, PSMC6, PSMC1, PSMC4, PSMC2, PSMC5, PSMD11, PSMD7, PSMD1, PSMD2, PSMD8, PSMD6, PSMC3, PSMD12, PSMD13, PSMD3, PSMD14, PSMD4, PSME1, PSMD5, PSME3, PSMA8, UBA52, RAD23B, TST, UBE2A, PYGB, FOLR1, YBX1, HRAS, SMARCA2, TUBB, C11orf58, PIR, UBE2B, SEC23A, VIM, SULT1A4, FN1, VCAM1, IQCB1, ITGA4, PARK2, GPX2, DDX49, CDK20, HOXA2, PYCRL, ASB11, KRT13, KCTD9, AMFR, SYVN1, PSMB9, HSPB1, AMBRA1, ACACA, ASNA1, ADRM1, MRPS9, PGK1, YWHAE, XPOT, PTEN, MCM2, POU5F1, UBLCP1, PSME4, AKIRIN2, PSMG2, PSME2, PSMF1, FBXO7, PSMG1, CYLD |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for SGMS1_PSMB2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | PSMB2 | P49721 | DB08889 | Carfilzomib | Proteasome subunit beta type-2 | small molecule | approved|investigational |
Top |
RelatedDiseases for SGMS1_PSMB2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | PSMB2 | C0005695 | Bladder Neoplasm | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|